Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results.

ABSTRACT:

Purpose

The objective was to describe PRDR outcomes and report EQD2 OAR toxicity thresholds.

Methods

Eighteen patients with recurrent primary CNS tumors treated with PRDR at a single institution between April 2017 and September 2021 were evaluated. The radiotherapy details, cumulative OAR doses, progression-free survival (PFS), overall survival (OS), and toxicities were collected.

Results

The median PRDR dose was 45 Gy (range: 36-59.4 Gy); the median cumulative EQD2 prescription dose was 102.7 Gy (range: 93.8-120.4 Gy). The median cumulative EQD2 D_0.03cc for the brain was 111.4 Gy (range: 82.4-175.2 Gy). Symptomatic radiation necrosis occurred in three patients, for which the median EQD2 brain D_0.03cc was 115.9 Gy (110.4-156.7 Gy). The median PFS

SUBMITTER: Kutuk T 

PROVIDER: S-EPMC9221236 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature